Streetbeat News

Stock Prices

GRAM

Glass House Brands CEO Kyle expressed optimism about California's future in the cannabis industry, highlighting the state's potential once regulatory constraints are removed. He noted the current challenges faced by retailers and brands in the cannabis market, advising investors to be cautious. Kyle also suggested that businesses relying on indoor cultivation and a large number of stores might need to reconsider their models to stay competitive.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:19 pm

NVDA

TSLA

Jim Cramer praised Nvidia's CEO, Jensen Huang, as a greater visionary than Tesla's Elon Musk, following Nvidia's strong Q4 earnings. Nvidia's success, driven by demand for its AI chips, contrasts with Tesla's recent underperformance. Cramer highlighted Nvidia's potential for continued growth and its impact on the tech industry.

Portfolio Pulse from Adam Eckert

February 22, 2024 | 6:17 pm

DASH

Financial giants are showing a bullish stance on DoorDash (NASDAQ:DASH) through options trading, with 65% of trades being bullish. The trading activity suggests a target price range of $100 to $165 for DASH in the next three months. DoorDash's current stock price is up 6.59% at $122.25, with analysts giving mixed ratings but an average target price of $134.8. The company has seen significant growth, with a 25% increase in gross order volume and a 31% increase in revenue year over year.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:16 pm

CRSP

Smart money investors have shown a bearish stance on CRISPR Therapeutics (NASDAQ:CRSP), with unusual options trading activity observed. Benzinga's options scanner revealed 26 significant trades, with a sentiment split of 38% bullish and 61% bearish. The trades suggest a price target range of $50.0 to $110.0 for CRSP over the next three months. The company, a leader in gene editing technology, is currently trading at $82.0, with a slight decrease of -0.5%. Its most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:15 pm

NVDA

HSBC analyst Frank Lee has maintained a Buy rating on NVIDIA (NASDAQ:NVDA) and increased the price target from $835 to $880, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:11 pm

D

Dominion Energy Inc (NYSE:D) shares fell after reporting Q4 FY23 results with revenue of $3.534 billion, missing the $4.206 billion consensus, and adjusted EPS of $0.29, below the $0.38 consensus. Operating earnings dropped across all segments, and the company announced a deal to sell a 50% stake in the Coastal Virginia offshore wind project to Stonepeak for $3 billion, expected to close by end of 2024.

Portfolio Pulse from Lekha Gupta

February 22, 2024 | 6:06 pm

EIS

SPY

USO

Yemen's Houthi rebels have announced they targeted an 'American Destroyer' in the Red Sea using a number of drones, according to Reuters. This incident could escalate tensions in the region, potentially affecting global markets and specific asset classes.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:04 pm

MNPR

Monopar Therapeutics Inc (NASDAQ:MNPR) shares surged 67.30% to $0.95 on high volume after announcing promising preclinical data for its MNPR-101 radiopharmaceutical program targeting cancers. The program showed significant tumor uptake and near-complete tumor elimination with a single injection. Additionally, Monopar received clearance in Australia to commence a Phase 1 trial of MNPR-101-Zr in patients with advanced cancers.

Portfolio Pulse from Vandana Singh

February 22, 2024 | 6:02 pm

BLK

FTNT

JEPQ

SHAK

On CNBC's Halftime Report, analysts shared their final trades, highlighting Shake Shack (SHAK), Fortinet (FTNT), BlackRock (BLK), and JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) as notable picks. These recommendations provide insights into potential stock movements based on the analysts' perspectives.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:01 pm

CCRN

Cross Country Healthcare (NASDAQ:CCRN) has received mixed analyst ratings over the past quarter, with recent evaluations adjusting price targets and ratings due to changing market dynamics and company performance. The average 12-month price target is now $21.25, a 15.0% decrease from the previous $25.00. Analysts from Truist Securities, Benchmark, UBS, and Barrington Research have adjusted their ratings and price targets, reflecting concerns over the company's revenue decline of -30.47% as of September 30, 2023, and operational challenges. Despite this, CCRN's net margin and ROE outperform industry benchmarks, indicating efficient cost management and financial health.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:00 pm